TapewireFind a company

person · Reporting owner

Zoghbi Huda Y

Disclosed activity across 1 company

Tapewire entity
24351
SEC CIK
0001681643

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
REGENERON PHARMACEUTICALS, INC.REGN · Entity 2010DirectorAugust 10, 2026August 12, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

REGENERON PHARMACEUTICALS, INC.

Report date August 10, 2026 · Filed August 12, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect1,703 Ending reported balance After 2026-08-10 transaction · row 2
2 source rows · reconciled sequence

Row 1 · 2026-08-10 · Exercise / conversion · Acquired 800 · Balance 2,503

F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 20, 2025.

Row 2 · 2026-08-10 · Sale · Disposed 800 · Balance 1,703

F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 20, 2025.

Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $376.69 · Expires 2027-01-03Direct0 Reported balance After 2026-08-10 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2026-08-10 · Exercise / conversion · Disposed 800 · Balance 0

F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 20, 2025.

F2: The stock option vested in three equal annual installments, commencing one year after the date of grant.

Filing footnotes · ownership attribution and instrument terms

F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 20, 2025.

F2: The stock option vested in three equal annual installments, commencing one year after the date of grant.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
August 10, 2026 Filed Aug 12, 2026 20:14 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative 800 $0.00 Strike: $376.69 $0.00
Disclosure

SEC source: 0001681643-26-000006 · edgardoc.xml · derivative · entry 3

Zoghbi Huda Y · CIK 0001681643 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 800 shares

Expires 2027-01-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 20, 2025.

F2 · derivative.exercise_date: The stock option vested in three equal annual installments, commencing one year after the date of grant.

Read SEC document
August 10, 2026 Filed Aug 12, 2026 20:14 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 SaleCommon Stock 800 $800.00 $640,000.00
Disclosure

SEC source: 0001681643-26-000006 · edgardoc.xml · nonDerivative · entry 2

Zoghbi Huda Y · CIK 0001681643 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,703

F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 20, 2025.

Read SEC document
August 10, 2026 Filed Aug 12, 2026 20:14 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 Exercise / conversionCommon Stock 800 $376.69 $301,352.00
Disclosure

SEC source: 0001681643-26-000006 · edgardoc.xml · nonDerivative · entry 1

Zoghbi Huda Y · CIK 0001681643 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,503

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 20, 2025.

Read SEC document
February 19, 2026 Filed Feb 23, 2026 21:55 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative 1,638 $0.00 Strike: $376.69 $0.00
Disclosure

SEC source: 0001681643-26-000004 · edgardoc.xml · derivative · entry 13

Zoghbi Huda Y · CIK 0001681643 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 800

Underlying: Common Stock · 1,638 shares

Expires 2027-01-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 20, 2025.

F10 · derivative.exercise_date: The stock option vested in three equal annual installments, commencing one year after the date of grant.

Read SEC document
February 19, 2026 Filed Feb 23, 2026 21:55 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 SaleCommon Stock 4 $790.00 $3,160.00
Disclosure

SEC source: 0001681643-26-000004 · edgardoc.xml · nonDerivative · entry 12

Zoghbi Huda Y · CIK 0001681643 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,703

F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 20, 2025.

Read SEC document
February 19, 2026 Filed Feb 23, 2026 21:55 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 SaleCommon Stock 56 $785.61 $43,994.16
Disclosure

SEC source: 0001681643-26-000004 · edgardoc.xml · nonDerivative · entry 11

Zoghbi Huda Y · CIK 0001681643 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,707

F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 20, 2025.

F9 · price: Represents volume-weighted average price of sales of 56 shares of Company stock on February 19, 2026 at prices ranging from $785.60 to $785.75. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 19, 2026 at each separate price.

Read SEC document
February 19, 2026 Filed Feb 23, 2026 21:55 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 SaleCommon Stock 160 $784.45 $125,512.00
Disclosure

SEC source: 0001681643-26-000004 · edgardoc.xml · nonDerivative · entry 10

Zoghbi Huda Y · CIK 0001681643 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,763

F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 20, 2025.

F8 · price: Represents volume-weighted average price of sales of 160 shares of Company stock on February 19, 2026 at prices ranging from $784.14 to $784.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 19, 2026 at each separate price.

Read SEC document
February 19, 2026 Filed Feb 23, 2026 21:55 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 SaleCommon Stock 220 $783.29 $172,323.80
Disclosure

SEC source: 0001681643-26-000004 · edgardoc.xml · nonDerivative · entry 9

Zoghbi Huda Y · CIK 0001681643 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,923

F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 20, 2025.

F7 · price: Represents volume-weighted average price of sales of 220 shares of Company stock on February 19, 2026 at prices ranging from $783.00 to $783.86. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 19, 2026 at each separate price.

Read SEC document
February 19, 2026 Filed Feb 23, 2026 21:55 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 SaleCommon Stock 298 $782.10 $233,065.80
Disclosure

SEC source: 0001681643-26-000004 · edgardoc.xml · nonDerivative · entry 8

Zoghbi Huda Y · CIK 0001681643 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,143

F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 20, 2025.

F6 · price: Represents volume-weighted average price of sales of 298 shares of Company stock on February 19, 2026 at prices ranging from $782.01 to $782.91. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 19, 2026 at each separate price.

Read SEC document
February 19, 2026 Filed Feb 23, 2026 21:55 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 SaleCommon Stock 209 $781.28 $163,287.52
Disclosure

SEC source: 0001681643-26-000004 · edgardoc.xml · nonDerivative · entry 7

Zoghbi Huda Y · CIK 0001681643 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,441

F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 20, 2025.

F5 · price: Represents volume-weighted average price of sales of 209 shares of Company stock on February 19, 2026 at prices ranging from $781.10 to $781.91. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 19, 2026 at each separate price.

Read SEC document
February 19, 2026 Filed Feb 23, 2026 21:55 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 SaleCommon Stock 331 $780.45 $258,328.95
Disclosure

SEC source: 0001681643-26-000004 · edgardoc.xml · nonDerivative · entry 6

Zoghbi Huda Y · CIK 0001681643 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,650

F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 20, 2025.

F4 · price: Represents volume-weighted average price of sales of 331 shares of Company stock on February 19, 2026 at prices ranging from $780.06 to $780.68. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 19, 2026 at each separate price.

Read SEC document
February 19, 2026 Filed Feb 23, 2026 21:55 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 SaleCommon Stock 208 $779.55 $162,146.40
Disclosure

SEC source: 0001681643-26-000004 · edgardoc.xml · nonDerivative · entry 5

Zoghbi Huda Y · CIK 0001681643 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,981

F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 20, 2025.

F3 · price: Represents volume-weighted average price of sales of 208 shares of Company stock on February 19, 2026 at prices ranging from $779.10 to $779.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 19, 2026 at each separate price.

Read SEC document
February 19, 2026 Filed Feb 23, 2026 21:55 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 SaleCommon Stock 53 $778.47 $41,258.91
Disclosure

SEC source: 0001681643-26-000004 · edgardoc.xml · nonDerivative · entry 4

Zoghbi Huda Y · CIK 0001681643 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,189

F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 20, 2025.

F2 · price: Represents volume-weighted average price of sales of 53 shares of Company stock on February 19, 2026 at prices ranging from $778.46 to $778.90. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 19, 2026 at each separate price.

Read SEC document
February 19, 2026 Filed Feb 23, 2026 21:55 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 SaleCommon Stock 50 $775.50 $38,775.00
Disclosure

SEC source: 0001681643-26-000004 · edgardoc.xml · nonDerivative · entry 3

Zoghbi Huda Y · CIK 0001681643 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,242

F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 20, 2025.

Read SEC document
February 19, 2026 Filed Feb 23, 2026 21:55 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 SaleCommon Stock 49 $774.68 $37,959.32
Disclosure

SEC source: 0001681643-26-000004 · edgardoc.xml · nonDerivative · entry 2

Zoghbi Huda Y · CIK 0001681643 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,292

F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 20, 2025.

Read SEC document
February 19, 2026 Filed Feb 23, 2026 21:55 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 Exercise / conversionCommon Stock 1,638 $376.69 $617,018.22
Disclosure

SEC source: 0001681643-26-000004 · edgardoc.xml · nonDerivative · entry 1

Zoghbi Huda Y · CIK 0001681643 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,341

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 20, 2025.

Read SEC document
January 02, 2026 Filed Jan 6, 2026 21:21 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 GrantNon-Qualified Stock Option (right to buy) · Derivative 1,962 $0.00 Strike: $772.76 $0.00
Disclosure

SEC source: 0001681643-26-000002 · edgardoc.xml · derivative · entry 2

Zoghbi Huda Y · CIK 0001681643 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,962

Underlying: Common Stock · 1,962 shares

Expires 2036-01-02

F2 · derivative.exercise_date: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant.

Read SEC document
January 02, 2026 Filed Jan 6, 2026 21:21 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 GrantCommon Stock 155 $0.00 $0.00
Disclosure

SEC source: 0001681643-26-000002 · edgardoc.xml · nonDerivative · entry 1

Zoghbi Huda Y · CIK 0001681643 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,703

F1 · kind: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock.

Read SEC document
January 02, 2025 Filed Jan 6, 2025 21:11 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 GrantNon-Qualified Stock Option (right to buy) · Derivative 1,958 $0.00 Strike: $719.37 $0.00
Disclosure

SEC source: 0001968202-25-000009 · edgardoc.xml · derivative · entry 2

Zoghbi Huda Y · CIK 0001681643 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,958

Underlying: Common Stock · 1,958 shares

Expires 2035-01-02

F2 · derivative.exercise_date: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant.

Read SEC document
January 02, 2025 Filed Jan 6, 2025 21:11 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 GrantCommon Stock 166 $0.00 $0.00
Disclosure

SEC source: 0001968202-25-000009 · edgardoc.xml · nonDerivative · entry 1

Zoghbi Huda Y · CIK 0001681643 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,548

F1 · kind: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock.

Read SEC document
January 02, 2024 Filed Jan 4, 2024 21:11 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 GrantNon-Qualified Stock Option (right to buy) · Derivative 1,607 $0.00 Strike: $888.34 $0.00
Disclosure

SEC source: 0001968202-24-000028 · edgardoc.xml · derivative · entry 5

Zoghbi Huda Y · CIK 0001681643 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,607

Underlying: Common Stock · 1,607 shares

Expires 2034-01-02

F4 · derivative.exercise_date: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant.

Read SEC document
January 02, 2024 Filed Jan 4, 2024 21:11 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative 1,117 $0.00 Strike: $391.92 $0.00
Disclosure

SEC source: 0001968202-24-000028 · edgardoc.xml · derivative · entry 4

Zoghbi Huda Y · CIK 0001681643 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,117 shares

Expires 2026-09-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 5, 2023.

F3 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant.

Read SEC document
January 02, 2024 Filed Jan 4, 2024 21:11 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 GrantCommon Stock 135 $0.00 $0.00
Disclosure

SEC source: 0001968202-24-000028 · edgardoc.xml · nonDerivative · entry 3

Zoghbi Huda Y · CIK 0001681643 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,382

F2 · kind: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock.

Read SEC document
January 02, 2024 Filed Jan 4, 2024 21:11 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 SaleCommon Stock 1,117 $900.00 $1,005,300.00
Disclosure

SEC source: 0001968202-24-000028 · edgardoc.xml · nonDerivative · entry 2

Zoghbi Huda Y · CIK 0001681643 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,247

F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 5, 2023.

Read SEC document
January 02, 2024 Filed Jan 4, 2024 21:11 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 Exercise / conversionCommon Stock 1,117 $391.92 $437,774.64
Disclosure

SEC source: 0001968202-24-000028 · edgardoc.xml · nonDerivative · entry 1

Zoghbi Huda Y · CIK 0001681643 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,364

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 5, 2023.

Read SEC document
October 13, 2023 Filed Oct 17, 2023 20:06 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative 1,000 $0.00 Strike: $391.92 $0.00
Disclosure

SEC source: 0001968202-23-000037 · edgardoc.xml · derivative · entry 3

Zoghbi Huda Y · CIK 0001681643 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,117

Underlying: Common Stock · 1,000 shares

Expires 2026-09-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 5, 2023.

F2 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant.

Read SEC document
October 13, 2023 Filed Oct 17, 2023 20:06 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 SaleCommon Stock 1,000 $850.00 $850,000.00
Disclosure

SEC source: 0001968202-23-000037 · edgardoc.xml · nonDerivative · entry 2

Zoghbi Huda Y · CIK 0001681643 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,247

F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 5, 2023.

Read SEC document
October 13, 2023 Filed Oct 17, 2023 20:06 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 Exercise / conversionCommon Stock 1,000 $391.92 $391,920.00
Disclosure

SEC source: 0001968202-23-000037 · edgardoc.xml · nonDerivative · entry 1

Zoghbi Huda Y · CIK 0001681643 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,247

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 5, 2023.

Read SEC document
January 03, 2023 Filed Jan 5, 2023 21:15 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 GrantNon-Qualified Stock Option (right to buy) · Derivative 1,929 $0.00 Strike: $725.89 $0.00
Disclosure

SEC source: 0001883850-23-000013 · edgardoc.xml · derivative · entry 2

Zoghbi Huda Y · CIK 0001681643 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,929

Underlying: Common Stock · 1,929 shares

Expires 2033-01-03

F2 · derivative.exercise_date: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant.

Read SEC document
January 03, 2023 Filed Jan 5, 2023 21:15 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 GrantCommon Stock 165 $0.00 $0.00
Disclosure

SEC source: 0001883850-23-000013 · edgardoc.xml · nonDerivative · entry 1

Zoghbi Huda Y · CIK 0001681643 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,247

F1 · kind: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock.

Read SEC document
March 16, 2022 Filed Mar 18, 2022 20:14 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative 2,000 $0.00 Strike: $391.92 $0.00
Disclosure

SEC source: 0001708138-22-000024 · edgardoc.xml · derivative · entry 3

Zoghbi Huda Y · CIK 0001681643 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,117

Underlying: Common Stock · 2,000 shares

Expires 2026-09-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

F2 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant.

Read SEC document
March 16, 2022 Filed Mar 18, 2022 20:14 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 SaleCommon Stock 2,000 $675.00 $1,350,000.00
Disclosure

SEC source: 0001708138-22-000024 · edgardoc.xml · nonDerivative · entry 2

Zoghbi Huda Y · CIK 0001681643 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,082

F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

Read SEC document
March 16, 2022 Filed Mar 18, 2022 20:14 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 Exercise / conversionCommon Stock 2,000 $391.92 $783,840.00
Disclosure

SEC source: 0001708138-22-000024 · edgardoc.xml · nonDerivative · entry 1

Zoghbi Huda Y · CIK 0001681643 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,082

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

Read SEC document
January 03, 2022 Filed Jan 5, 2022 21:24 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 GrantNon-Qualified Stock Option (right to buy) · Derivative 2,707 $0.00 Strike: $625.60 $0.00
Disclosure

SEC source: 0001883850-22-000009 · edgardoc.xml · derivative · entry 2

Zoghbi Huda Y · CIK 0001681643 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,707

Underlying: Common Stock · 2,707 shares

Expires 2032-01-03

F2 · derivative.exercise_date: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant.

Read SEC document
January 03, 2022 Filed Jan 5, 2022 21:24 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 GrantCommon Stock 191 $0.00 $0.00
Disclosure

SEC source: 0001883850-22-000009 · edgardoc.xml · nonDerivative · entry 1

Zoghbi Huda Y · CIK 0001681643 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,082

F1 · kind: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock.

Read SEC document
September 14, 2021 Filed Sep 15, 2021 20:03 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative 998 $0.00 Strike: $391.92 $0.00
Disclosure

SEC source: 0001708138-21-000081 · edgardoc.xml · derivative · entry 6

Zoghbi Huda Y · CIK 0001681643 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,117

Underlying: Common Stock · 998 shares

Expires 2026-09-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

F2 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant.

Read SEC document
September 14, 2021 Filed Sep 15, 2021 20:03 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 SaleCommon Stock 998 $650.00 $648,700.00
Disclosure

SEC source: 0001708138-21-000081 · edgardoc.xml · nonDerivative · entry 4

Zoghbi Huda Y · CIK 0001681643 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 891

F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

Read SEC document
September 14, 2021 Filed Sep 15, 2021 20:03 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 Exercise / conversionCommon Stock 998 $391.92 $391,136.16
Disclosure

SEC source: 0001708138-21-000081 · edgardoc.xml · nonDerivative · entry 3

Zoghbi Huda Y · CIK 0001681643 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,889

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

Read SEC document
September 13, 2021 Filed Sep 15, 2021 20:03 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative 2 $0.00 Strike: $391.92 $0.00
Disclosure

SEC source: 0001708138-21-000081 · edgardoc.xml · derivative · entry 5

Zoghbi Huda Y · CIK 0001681643 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,115

Underlying: Common Stock · 2 shares

Expires 2026-09-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

F2 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant.

Read SEC document
September 13, 2021 Filed Sep 15, 2021 20:03 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 SaleCommon Stock 2 $651.10 $1,302.20
Disclosure

SEC source: 0001708138-21-000081 · edgardoc.xml · nonDerivative · entry 2

Zoghbi Huda Y · CIK 0001681643 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 891

F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

Read SEC document
September 13, 2021 Filed Sep 15, 2021 20:03 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 Exercise / conversionCommon Stock 2 $391.92 $783.84
Disclosure

SEC source: 0001708138-21-000081 · edgardoc.xml · nonDerivative · entry 1

Zoghbi Huda Y · CIK 0001681643 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 893

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

Read SEC document
January 04, 2021 Filed Jan 5, 2021 21:11 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 GrantNon-Qualified Stock Option (right to buy) · Derivative 3,613 $0.00 Strike: $482.68 $0.00
Disclosure

SEC source: 0001708138-21-000010 · edgardoc.xml · derivative · entry 2

Zoghbi Huda Y · CIK 0001681643 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,613

Underlying: Common Stock · 3,613 shares

Expires 2031-01-04

F2 · derivative.exercise_date: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant.

Read SEC document
January 04, 2021 Filed Jan 5, 2021 21:11 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 GrantCommon Stock 248 $0.00 $0.00
Disclosure

SEC source: 0001708138-21-000010 · edgardoc.xml · nonDerivative · entry 1

Zoghbi Huda Y · CIK 0001681643 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 891

F1 · kind: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock.

Read SEC document
July 07, 2020 Filed Jul 8, 2020 20:14 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative 1,706 $0.00 Strike: $391.92 $0.00
Disclosure

SEC source: 0001237899-20-000028 · edgardoc.xml · derivative · entry 3

Zoghbi Huda Y · CIK 0001681643 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,117

Underlying: Common Stock · 1,706 shares

Expires 2026-09-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

F2 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant.

Read SEC document
July 07, 2020 Filed Jul 8, 2020 20:14 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 SaleCommon Stock 1,706 $650.00 $1,108,900.00
Disclosure

SEC source: 0001237899-20-000028 · edgardoc.xml · nonDerivative · entry 2

Zoghbi Huda Y · CIK 0001681643 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 643

F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

Read SEC document
July 07, 2020 Filed Jul 8, 2020 20:14 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 Exercise / conversionCommon Stock 1,706 $391.92 $668,615.52
Disclosure

SEC source: 0001237899-20-000028 · edgardoc.xml · nonDerivative · entry 1

Zoghbi Huda Y · CIK 0001681643 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,349

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

Read SEC document
June 11, 2020 Filed Jun 12, 2020 20:03 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative 1,706 $0.00 Strike: $391.92 $0.00
Disclosure

SEC source: 0001708138-20-000072 · edgardoc.xml · derivative · entry 15

Zoghbi Huda Y · CIK 0001681643 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,823

Underlying: Common Stock · 1,706 shares

Expires 2026-09-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

F9 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant.

Read SEC document
June 11, 2020 Filed Jun 12, 2020 20:03 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 SaleCommon Stock 1,706 $625.00 $1,066,250.00
Disclosure

SEC source: 0001708138-20-000072 · edgardoc.xml · nonDerivative · entry 13

Zoghbi Huda Y · CIK 0001681643 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 643

F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

Read SEC document
June 11, 2020 Filed Jun 12, 2020 20:03 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 Exercise / conversionCommon Stock 1,706 $391.92 $668,615.52
Disclosure

SEC source: 0001708138-20-000072 · edgardoc.xml · nonDerivative · entry 12

Zoghbi Huda Y · CIK 0001681643 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,349

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

Read SEC document
June 10, 2020 Filed Jun 12, 2020 20:03 UTC REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative 1,706 $0.00 Strike: $391.92 $0.00
Disclosure

SEC source: 0001708138-20-000072 · edgardoc.xml · derivative · entry 14

Zoghbi Huda Y · CIK 0001681643 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,529

Underlying: Common Stock · 1,706 shares

Expires 2026-09-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

F9 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.